日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind, Clinical Trial

TRC150094，一种新型线粒体调节剂，作为附加治疗可降低心血管代谢风险：一项为期 24 周的多中心、随机、双盲 II 期临床试验

期刊:Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
影响因子:3
doi:10.2147/DMSO.S330515
Joshi, Deepa; Gj, Prashant; Ghosh, Shohini; Mohanan, Anookh; Joshi, Shashank; Mohan, Viswanathan; Chowdhury, Subhankar; Dutt, Chaitanya; Tandon, Nikhil
线粒体
代谢
发表日期：2022
文献求助 收藏

Safety, Tolerability, and Pharmacokinetics of a Novel Mitochondrial Modulator, TRC150094, in Overweight and Obese Subjects: A Randomized Phase-I Clinical Trial

新型线粒体调节剂TRC150094在超重和肥胖受试者中的安全性、耐受性和药代动力学：一项随机I期临床试验

期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2021.729424
Joshi, Deepa; Jamadarkhana, Prashant; Kumbhare, Suchit; Singh, Amarinder; Kotecha, Jignesh; Bunger, Deepak; Shiwalkar, Ajay; Mohanan, Anookh; Dutt, Chaitanya
肥胖
线粒体
代谢
发表日期：2021
文献求助 收藏

TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats

TRC120038，一种新型双重AT(1)/ET(A)受体阻滞剂，用于控制ob-ZSF1大鼠的高血压、糖尿病肾病和心肌病

期刊:International Journal of Hypertension
影响因子:1.7
doi:10.4061/2011/751513
Mohanan, Anookh; Gupta, Ram; Dubey, Amita; Jagtap, Vikrant; Mandhare, Appaji; Gupta, Ramesh C; Chauthaiwale, Vijay; Dutt, Chaitanya
心肌病
高血压
信号转导
心血管
Rat
代谢
糖尿病
糖尿病肾病
发表日期：2011
文献求助 收藏